Biofrontera(BFRI) - 2023 Q4 - Annual Report
Biofrontera(BFRI)2024-03-16 05:00
Our principal licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLEDlamp series, for PDT (when used together, "Ameluz PDT"). In the United States, the PDT treatment is used for the lesion-directed and fielddirected treatment of actinic keratoses ("AK") of mild-to-moderate severity on the face and scalp. AKs are premalignant lesions of the skin that can potentially develop into skin cancer (squamous cell carcinoma) if left untreated.International treatment ...